Key Facts

Invested since 2006
Based in Bavaria

About the company

Corimmun is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative peptide and biological drugs in indications with unmet medical needs.

Exit since June 2012.

Do you want to

know more about this company?

Zum Artikel

Marco Winzer Partner

Marco WinzerPartner

Corimmun in the news

Zum Artikel

Press

26. July 2012

Investors Realize exit VIA Trade Sale of Portfolio Company Corimmun GmbH

Zum Artikel

Press

22. September 2008

Corimmun GmbH closes a EUR 5million financing round with MIG AG as lead investor

More startups from Life Sciences